Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited («fast track») pathways, finds a study published by The BMJ.
Significant proportion of cancer drugs lack proof of added benefit, finds study
Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited ("fast track") pathways, finds a study published by The BMJ.